Summit reports updated HARMONi overall survival data at WCLC 2026Sep 15Clinical readoutivonescimabSummit Therapeutics
Summit Therapeutics registers Phase 2/3 HARMONi-GU1 trial in urothelial carcinomaSep 11Trial updateivonescimabSummit Therapeutics
Summit's partner Akeso reports positive Phase III data for ivonescimab in bile duct cancerAug 26Clinical readoutivonescimabSummit Therapeutics
MD Anderson registers Phase II trial of Summit's ivonescimab in rare appendix cancerAug 10Trial updateivonescimabSummit Therapeutics
Summit Therapeutics starts Phase II/III bladder cancer trial for ivonescimabAug 5Clinical readoutivonescimabSummit Therapeutics
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
MD Anderson registers Phase 2 trial of Summit's ivonescimab in rare adrenal cancersAug 3Trial updateivonescimabSummit Therapeutics
Summit reports Q2 2026 results as HARMONi OS data hold up in western patientsJul 23Clinical readoutGlaxoSmithKlineivonescimab
Summit Therapeutics discloses going concern doubt alongside $380 million stock offeringJul 23FinancingivonescimabSummit Therapeutics
Sign inSign in